Trial
NCT03848832
Efficacy and Safety of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome
Phase IIITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Jazz Pharmaceuticals
Collaborators
—
Condition
Rett Syndrome
Intervention
GWP42003-P
Why stopped
The study was terminated due to enrollment challenges and the COVID-19 pandemic.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-09-02